Glaucoma
An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
Subtype terms (4)
More specific conditions that are subtypes of Glaucoma in the MeSH hierarchy.
- Glaucoma, Angle-Closure
16 drugs (12 approved, 4 experimental)
- Glaucoma, Neovascular
14 drugs (11 approved, 3 experimental)
- Glaucoma, Open-Angle
130 drugs (61 approved, 69 experimental)
- Low Tension Glaucoma
10 drugs (7 approved, 3 experimental)
Drugs by status
Approved for this indication (19)
Phase 4 trials (28)
- nitrous oxide
- diclofenac
- bromfenac
- prednisone
- fluorouracil
- rosuvastatin
- insulin human
- netarsudil
- hyaluronic acid
- semaglutide
- bevacizumab
- loteprednol
- collagen
- cellulose
- dexmedetomidine
- carotenoid
- triamcinolone
- carteolol
- oxygen
- prednisolone
- sodium chloride
- prostaglandin
- hypromelloses
- mexidol
- dexamethasone
- ginkgo biloba
- citicoline
- methylcellulose
Phase 3 trials (25)
Phase 2 trials (29)
- simenepag isopropyl
- ama-0076
- dnb-001
- palmitoylethanolamide
- niacin
- aqueous mushroom extract
- sepetoprost
- plx51107
- lidocaine
- prm-151
- qpi-1007
- verosudil
- rki983
- cannabis
- syl040012
- zeaxanthin
- antisecretory factor
- multivitamins
- etacrynic acid
- ib-meca
- quinine
- prilocaine
- lutein
- revakinagene taroretcel
- mesozeaxanthin
- qls-101
- kinezodianone
- qls-111
- gvb-2001
Phase 1 trials (16)
Organizations
Organization Involved with Phase 4 Indications (113)
- Aeon Astron Europe B.V.
- Pfizer
- Novartis
- Aerie Pharmaceuticals
- Bp Consulting, Inc
- Santen Inc.
- FinnMedi Oy
- Glaukos Corporation
- Hanlim Pharm. Co., Ltd.
- Intuor Technologies, Inc.
- Laboratoires Thea
- Ocular Therapeutix, Inc.
- Pro Top & Mediking Company Limited
- Vistakon Pharmaceuticals
- Credit Valley EyeCare
- Genovate Biotechnology Co., Ltd.,
- Taejoon Pharm Co., Ltd.
- Fondazione G.B. Bietti, IRCCS
- I.R.C.C.S. Fondazione Santa Lucia
- National Eye Institute (NEI)
- Dr. Anton Hommer
- DBYAN Medicine Professional Corporation
- Nova Scotia Health Authority
- University of Pittsburgh
- Bascom Palmer Eye Institute
- Beirut Eye Specialist Hospital
- Cornerstone Health Care, PA
- Harvard University
- Glaucoma Associates of New York
- Indiana University
- +83 more
Organization Involved with Phase 3 Indications (51)
- PPD
- Actavis
- Regeneron
- Adapt Produtos Oftalmológicos Ltda.
- Genentech
- Perrigo
- Alfred E. Tiefenbacher (GmbH & Co. KG)
- Bayer
- Gene Signal SAS
- Laboratorios Sophia S.A de C.V.
- NicOx
- Sun Pharmaceuticals
- Chong Kun Dang Pharmaceutical
- Otsuka
- Nephron Pharmaceuticals Corporation
- Shahid Beheshti University of Medical Sciences
- Alexandria University
- Athens Vision Eye Institute
- University of London
- Duke University
- Semmelweis University
- Singapore Eye Research Institute
- Singapore National Eye Centre
- Universidad Complutense de Madrid
- University of Miami
- University of Milan
- University of Oulu
- University of Tartu
- Prince of Songkla University
- Xiamen University
- +21 more
Organization Involved with Phase 2 Indications (57)
- Novelion Therapeutics
- Acucela Inc.
- Bausch Health Companies
- Roche
- Alleanza Pharmaceuticals, Inc.
- Aerpio Therapeutics
- American Society Of Thermalism And Climatology Inc
- Can-Fite BioPharma
- GliaCure, Inc.
- Lexicon Pharmaceuticals
- Mati Therapeutics Inc.
- Othera Pharmaceuticals
- Peregrine Ophthalmic
- Promedior, Inc.
- pH Pharma
- Altheos, Inc.
- Amakem, NV
- Envisia Therapeutics
- PharmaMar
- Quark Pharmaceuticals
- BioLight
- National Centre of Ophthalmology named after academician Zarifa Aliyeva
- World Health Organization
- Nanduri, Padma, M.D., FACS
- California Retina Consultants
- Mashhad University of Medical Sciences
- New York Glaucoma Research Institute
- St. Erik Eye Hospital
- University of East Anglia
- University of Maryland
- +27 more
Organization Involved with Phase 1 Indications (20)
- Inspire Pharmaceuticals
- Shire
- Sanofi
- Eye Therapies, LLC
- Isarna Therapeutics GmbH
- Merz
- Noveome Biotherapeutics
- Paloma Pharmaceuticals, Inc.
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Johns Hopkins University
- Medical University of Lublin
- Texas Retina Associates
- University of Florida
- University of Kentucky
- University of Melbourne
- Annexon
- Wellcome Trust
- Cromsource
- Dompe Pharmaceuticals
- PolyActiva
Organization Involved with Other Experimental Indications (31)
- Aurolab
- United States Army
- University of Roma La Sapienza
- Shanghai Jinshan Hospital
- Advanced Glaucoma Specialists
- Cairo University
- Hermann Eye Center
- Hospital Governador Celso Ramos
- Philadelphia Eye Associates
- Queen's University, Belfast
- Qingdao University
- University of Bologna
- Columbia University
- Fudan University
- Tel Aviv University
- Umea University
- Hebrew University
- University of Lubeck
- Catholic University of Korea
- University of Texas at Houston
- Aravind Eye Hospital
- University of Kwa-Zulu Natal
- Kisii Eye Hospital, Kenya
- Menelik II Hospital
- University of Picardie Jules Verne
- Gsap Medical Ltd.
- Eximore Ltd.
- Istituto di Ricerca Neuroftalmologia S.r.l.
- University of Molise
- Medivis
- +1 more